BTEC:SW:SW-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) USD (USD)

ETF | Others |

Last Closing

USD 6.43

Change

+0.07 (+1.13)%

Market Cap

USD 0.45B

Volume

0.05M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-28 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
RGLDS:SW Raiffeisen ETF Solid Gold A US..

-13.00 (-0.18%)

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

+33.50 (+0.70%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

+14.40 (+0.96%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

+3.50 (+0.17%)

USD 134,034.85B
SX7EEX:SW iShares EURO STOXX Banks 30-15..

+0.04 (+0.31%)

USD 6,289.31B
TDXPEX:SW iShares TecDAX® UCITS ETF (DE..

+0.35 (+1.18%)

USD 5,933.97B
SMIEX:SW iShares SLI UCITS ETF (DE)

+1.10 (+0.86%)

USD 5,933.96B
DJSXE:SW iShares Core EURO STOXX 50 UCI..

N/A

USD 5,933.96B
DAXEX:SW iShares Core DAX® UCITS ETF (..

+0.92 (+0.63%)

USD 5,933.93B
MDAXEX:SW iShares MDAX® UCITS ETF (DE) ..

+0.05 (+0.02%)

USD 5,933.92B

ETFs Containing BTEC:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.70% 22% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.70% 21% F 24% F
Trailing 12 Months  
Capital Gain 9.75% 51% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.75% 51% F 53% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.15% 50% F 50% F
Dividend Return 1.15% 50% F 50% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 2.84% 70% C- 74% C
Risk Adjusted Return 40.47% 53% F 56% F
Market Capitalization 0.45B 63% D 59% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.